Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Q3 2023 Earnings Presentation
16 slides from Orion Oyj Class A's earnings presentation, Oct 26, 2023
Slide 1: Orion Interim Report January–September 2023
Orion Interim Report January–September 2023 26 October 2023
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Key matters in Q3 2023
Key matters in Q3 2023 • Development was positive both in terms of net sales and operating profit excluding the significant upfront payment in the comparative period • Strong growth for Nubeqa® • EUR 30 million sales milestone from Nubeqa® recorded for Q3 • Easyhaler® product portfolio sales develop
Slide 4: January-September 2023: Underlying business performed well and mostly as expected
January-September 2023: Underlying business performed well and mostly as expected Cash flow from • Net sales in January–September 2023 Net sales operating activities • Includes EUR 30 million sales milestone from Nubeqa® per share • Exceptional comparative period due to significant ODM-208 related u
Slide 5: Net sales bridge from YTD9 2022 to YTD9 2023
Net sales bridge from YTD9 2022 to YTD9 2023 1 Dexmedetomidine for human use and Simdax® 5 Other products and services (excl. Animal Health and Fermion) 2 Nubeqa® (product sales and royalty) 6 Animal Health and Fermion 3 Entacapone products 7 Milestones 4 Russia 8 Exchange rates 5 26 October 2023 ©
Slide 6: Operating profit bridge YTD9 2022 to YTD9 2023
Operating profit bridge YTD9 2022 to YTD9 2023 1 Product & service sales without sales margin and product mix change and exchange rate effect 5 Milestones 2 Product sales margin and product mix change but without exchange rate effect 6 Other operating income and expenses 3 Exchange rate effect on gr
Slide 7: Business reviews
Business reviews 450.0 Sales split in YTD9 2023 400.0 350.0 6% 300.0 9% 19% 250.0 MEUR 200.0 150.0 22% 100.0 44% 50.0 0.0 Innovative Medicines -50.0 Branded Products Innovative Branded Generics & Animal Fermion Other* Generics and Consumer Health Medicines Products Consumer Health Animal Health Heal
Slide 8: TOP 10 products in YTD9 2023
TOP 10 products in YTD9 2023 EUR vs. Product or product portfolio million YTD9 2022 1. Nubeqa® 120.3 >100% 2. Easyhaler® product portfolio 101.6 +8.5% 3. Entacapone products1 67.7 -24.6% 4. Simdax® 20.2 -39.1% 5. Burana® 18.3 -5.2% 6. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 18.2 -35.5% 7. Dexm
Slide 9: Innovative Medicines EUR 167.0 million (-42.5%) – Nubeqa sales more than doubled
Innovative Medicines EUR 167.0 million (-42.5%) – Nubeqa sales more than doubled • Decline due to significant EUR 228 million upfront Nubeqa® sales booked by Orion1 payment recorded in the comparative period 50 • Excluding the upfront payment, net sales more than 45 doubled 40 • Nubeqa® sales booked
Slide 10: Branded Products EUR 188.5 million (-10.7%)
Branded Products EUR 188.5 million (-10.7%) 120 • Easyhaler® product portfolio Sales split 101.6 continued on a solid growth 100 93.7 2% track 89.7 • The decline in entacapone 80 8% 67.7 mainly due to lower partner sales MEUR 60 • The decline in Divina® series 40 due to discontinuation of 36% 54% 20
Slide 11: Generics and Consumer Health EUR 383.6 million (-7.6%)
Generics and Consumer Health EUR 383.6 million (-7.6%) 350 • Generic competition pressing Sales split by geographic 312.0 the prices and sales of Simdax® 300 286.4 areas and dexmedetomidine products for human use 250 • Discontinuation of business 17% 200 operations in Russia also MEUR explains the n
Slide 12: Animal Health and Fermion
Animal Health and Fermion • Animal Health growth due to Animal Health Fermion acquisition of animal health 90 60 52.7 54.1 company VMD (Inovet) in June 80 77.1 2022 50 70 65.3 18.2 • However, in Q3 Animal Health 60 40 net sales declined from 50 28.3 comparative period due to MEUR 30 40 weakening dem
Slide 13: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide 1 Prostate cancer (mHSPC) ARASTEP / darolutamide 1 Prostate cancer (BCR) ODM-208 2 Prostate cancer (mCRPC) ODM-105 / tasipimidine Insomnia ODM-111 (NaV 1.8 blocker) Pain ODM-2
Slide 14: Orion is committed to maintaining biodiversity
Orion is committed to maintaining biodiversity – we are working to ensure that our business operations and value chain do not contribute to biodiversity loss ● We are actively seeking solutions to reduce the environmental impacts of the pharmaceutical industry in cooperation with other operators in
Slide 15: Outlook for 2023 (specified on 17 July 2023)
Outlook for 2023 (specified on 17 July 2023) Net sales Orion estimates that net sales in 2023 will be slightly higher than in 2022 without the EUR 228 million impact from ODM-208 upfront payment (net sales in 2022 without the impact of the ODM-208 upfront payment were EUR 1,113 million). Operating p
Slide 16: Upcoming events
Upcoming events Financial Statement Release for 2023 13/2/2024 AGM 2024 planned to be held on 20/3/2024 Interim Report 1–3/2024 25/4//2024 Half-Year Financial Report 1–6/2024 8/8/2024 Interim Report 1–9/2024 29/10/2024 16 26 October 2023 © Orion Corporation